Vyome Holdings, Inc. (HIND)

NCM – Real vaqt narxi. Valyuta: USD

2.18

-0.02 (-0.91%)

Bozor ochiq: Jun 17, 2026, 9:41 AM EDT

Kompaniya haqida

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5′-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Asosiy rahbarlar

Ism	Lavozim
Dr. Charles G. Chavdarian Ph.D.	Senior Vice President of Product Development & Regulatory CMC
Dr. Richard Fahrner Ph.D.	Chief Technology Officer
Dr. Shiladitya Sengupta M.Sc., Ph.D.	Co-Founder, Director and Member of Scientific & Clinical Advisory Board
Dr. Tamara Agajanov M.D.	Senior Vice President of Clinical Development
Mr. Robert Dickey IV	Chief Financial Officer
Mr. Venkateswarlu Nelabhotla M.B.A.